Why The Australian Medical Hashish Biz Isn’t As Attractive As It Thinks It’s

Who remembers Proper Stated Fred ?

OK you do need to be a bit of lengthy within the tooth however each time we hear Australian cannabis executives speak in regards to the “market” in our little navel gazing nation we’re reminded of this track.

Proper Stated Fred  truly perceive self -deprecation, we propose that’s a step too far for Australian cannabis sector “executives” although.

[embedded content]

So… we’re very glad to see a bit by new Australian cannabis media outfit , Cannabiz, who write by the use of introduction of their newest replace on the sector

Within the closing instalment of a three-part evaluation of Australia’s authorized cannabis panorama, Cannabiz chief correspondent Steve Jones examines the explanations behind the declining valuation of the trade’s listed enterprises.

In January 2018, buoyed by authorities clearance to export medicinal cannabis from Australia, Cann Group shares soared previous $4.

At this time they’re valued at 42 cents.

Over at Auscann, in the meantime, the early days of 2018 noticed shares hit $1.74. On the opening of enterprise yesterday they have been 14 cents.

Equally Althea. In July it peaked at $1.20 per share. Since then the worth has fallen 70%. Elixinol is one other to see its worth fall.

In reality, wherever you look within the ASX-listed medicinal cannabis sector, the sample is identical. Shares have suffered, virtually with out exception.

With native manufacturing gradual to take off, little significant income era, and profitability a distant ambition, that subdued image is unlikely to alter any time quickly.

Full article under

Evaluation: The Canadian massacre, investor warning and the battle to revive worth to the Australian cannabis sector

Latest posts